Industry news

Share this article:
The FDA, in partnership with Duke University, announced the executive board for its Clinical Trials Transformation Initiative. The board will be co-chaired by Duke vice chancellor for clinical research Dr. Robert Califf and Dr. Rachel Behrman, director of the Office of Critical Path Programs at FDA. Industry representation on the board includes: Susan Alpert, SVP and chief quality and regulatory officer at Medtronic; Glenn Gormley, SVP, global clinical development and medical affairs, Novartis Pharmaceuticals; and Jay Siegel, group president, R&D, biotechnology, immunology and oncology at Johnson & Johnson. 
Share this article:
You must be a registered member of MMM to post a comment.
close

Next Article in Channel

 

Did you miss January's Top 40 Healthcare Transformers issue? Read how these inventors, strategists, entrepreneurs and wonks are challenging, disrupting and otherwise transforming the healthcare business. And join us April 30 to honor them at the Transforming Healthcare Dinner. Click here.